Top of this page
Skip navigation, go straight to the content Patients Financial Assistance

Paying for Your Medication

UCB is committed to ensuring patients who need our medications can access them. If you are struggling with the burden of paying for your medication there are several types of financial assistance for qualified patients.

UCB Prescription Co-Pay Assistance Programs

image description

If you have been prescribed BRIVIACT® (brivaracetam) CV, 
CIMZIA® (certolizumab pegol), 
NEUPRO® (rotigotine transdermal system) or VIMPAT® (lacosamide) CV and would like to apply for a co-pay assistance card, please click on the appropriate link above. 



UCB Patient Assistance Program (PAP)

image description

If you need any financial assistance, you may qualify for the UCB Patient Assistance Program (PAP). You can access the online application here.


Online Application

Download the Application

Understanding your Insurance

image description

Choosing the right insurance plan for you and your family can be confusing. We’ve developed a guide to help you navigate the process.


 Download the Guide

Contact UCB Cares

Hours of Operation
8am-8pm ET Monday-Thursday
8am-5pm ET Friday
Phone Number: +1-844-599-CARE (2273)
Email Address:




At UCB, patients are at the heart of everything we do.

Working with physicians and other healthcare professionals, we engage with patients to better understand their clinical, economic, social and personal needs. What matters most is how we at UCB can add more value to support patients on their healthcare journeys. We’re not just treating a disease; we’re caring for individual people.

Staying true to these core beliefs, UCB is committed to ensuring patients, whose physicians have prescribed our medications, are able to access these products. Through the UCB Patient Assistance Program, we provide some medications at no cost to eligible and qualified patients who are uninsured or underinsured who otherwise have no access to the UCB medicines prescribed by their physician. We are committed to an ongoing dialogue with patients, healthcare professionals, insurance companies, policymakers and regulators to promote innovation and new medical discoveries while also doing our part to alleviate some of the cost burden for those living with severe diseases.